Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug

Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug

Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of Lilly’s drug, Retevmo. Both are RET inhibitors.

Source: https://ift.tt/3dkRvds